Streetbeat News

QURE

uniQure N.V.

https://www.uniqure.com

Industry

Biotechnology

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Open

14.98

Mkt cap

751M

Volume

2.6M

High

15.89

P/E Ratio

-3.24

52-wk high

17.39

Low

14.89

Div yield

N/A

52-wk low

3.73

uniQure's stock has surged by 152% in December due to positive news about its Huntington's disease candidate and FDA developments.

Portfolio Pulse from

December 15, 2024 | 9:45 am

uniQure's stock surged by 110% following an agreement with the FDA on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

Portfolio Pulse from

December 11, 2024 | 4:30 pm

Wall Street analysts have set a consensus price target for uniQure (QURE) that suggests a potential upside of 228.1%. Despite skepticism about the effectiveness of price targets, recent upward trends in earnings estimate revisions indicate a possible near-term increase in QURE's stock price.

Portfolio Pulse from

November 29, 2024 | 4:15 pm

uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could lead to a rise in its stock price.

Portfolio Pulse from

November 28, 2024 | 6:15 pm

Wall Street analysts have set an average price target for uniQure (QURE) that suggests a potential upside of 169.2%. Despite some skepticism about the reliability of this metric, positive trends in earnings estimate revisions could lead to a stock price increase.

Portfolio Pulse from

November 08, 2024 | 4:00 pm

uniQure has announced its third quarter 2024 financial results and highlighted recent progress, including a scheduled Type B meeting with the FDA to discuss an expedited clinical development pathway for AMT-130 in Huntington's disease.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

uniQure has initiated a Phase I/II clinical trial for AMT-162, a treatment for SOD1-ALS, with the first patient dosed. The trial, named EPISOD1, is being conducted in the US and will assess safety, tolerability, and exploratory efficacy across three dose-escalating cohorts.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:16 am

Raymond James analyst Danielle Brill has reinstated an Outperform rating on uniQure (NASDAQ:QURE) and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:05 pm

uniQure's AMT-191, a gene therapy for Fabry disease, has received Orphan Drug Designation from the FDA. This status supports uniQure's ongoing Phase I/IIa trial and offers incentives like tax credits and market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:07 am

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on uniQure (NASDAQ:QURE) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 4:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.